PTC Therapeutics, Inc. (PTCT) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Harmony Biosciences Holdings, Inc.

Madrigal Pharmaceuticals, Inc.

Corcept Therapeutics, Inc.

Cytokinetics, Inc.

PTC Therapeutics, Inc.

Xenon Pharmaceuticals, Inc.

Ultragenyx Pharmaceutical, Inc.

Amphastar Pharmaceuticals, Inc.

Akero Therapeutics, Inc.

Biohaven Ltd.

Neumora Therapeutics, Inc.

Why is PTC Therapeutics, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate 34.04% of over the last 5 years
Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times

Risky - Negative Book Value

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 92.91%, its profits have risen by 311.1% ; the PEG ratio of the company is 0

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is PTC Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

PTC Therapeutics, Inc.

54.8%

2.25

53.53%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

41.48%

EBIT Growth (5y)

34.04%

EBIT to Interest (avg)

-2.26

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

9.29

Sales to Capital Employed (avg)

16.42

Tax Ratio

8.68%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

-22.24

EV to EBIT

2.77

EV to EBITDA

2.69

EV to Capital Employed

-1.26

EV to Sales

1.36

PEG Ratio

0.02

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

28What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 704.78 MM

NET SALES(HY)

Higher at USD 1,354.97 MM

NET PROFIT(HY)

Higher at USD 801.14 MM

RAW MATERIAL COST(Y)

Fallen by -1.35% (YoY

CASH AND EQV(HY)

Highest at USD 4,016.33 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 9.21 times

-12What is not working for the Company

PRE-TAX PROFIT(Q)

At USD -70.95 MM has Fallen at -135.49%

NET PROFIT(Q)

At USD -64.75 MM has Fallen at -134.85%

DEBT-EQUITY RATIO (HY)

Highest at 775.12 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.99 times

NET SALES(Q)

Lowest at USD 178.88 MM

Here's what is working for PTC Therapeutics, Inc.

Operating Cash Flow

Highest at USD 704.78 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Cash and Eqv

Highest at USD 4,016.33 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debtors Turnover Ratio

Highest at 9.21 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -1.35% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at USD 7.58 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for PTC Therapeutics, Inc.

Net Sales

At USD 178.88 MM has Fallen at -59.64%

over average net sales of the previous four periods of USD 443.19 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -70.95 MM has Fallen at -135.49%

over average net sales of the previous four periods of USD 199.93 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -64.75 MM has Fallen at -134.85%

over average net sales of the previous four periods of USD 185.8 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Sales

Lowest at USD 178.88 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Debt-Equity Ratio

Highest at 775.12 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.99 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio